Escape Bio Was A Clinical Stage Biopharmaceutical Company Dedicated To Developing Precision Therapeutics For Genetically Defined Neurodegenerative Diseasessuch As Alzheimerae S And Parkinsonae Sthe Company Focused On Creating Small Molecule Drugs That Target Specific Genetic Pathways To Address The Root Causes Of Neurodegenerationescape Bio S Pipeline Included Several Candidatessuch As Esb1609A Phase 1 Drug Tested In Healthy Volunteersand A Lrrk2 G2019S Inhibitor For Parkinsonae S Patientsthey Also Worked On An Apoe4 Corrector Aimed At Alzheimerae S Patients With The Apoe4 Genetic Risk Allelethe Company Emphasized Disease Modifying Therapies And Precision Medicine To Slow Or Reverse Neurodegenerationdespite Raising Significant Funding And Collaborating With Academic And Industry Leadersescape Bio Ceased Operations In Early 2023 Without Commercializing Any Therapies
